Navigation Links
Targeted blocking of cell death prevents fatal condition septic shock
Date:12/27/2011

Ghent, Belgium 27 December 2011 - Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body. It is the most frequent cause of death at intensive care departments in hospitals. In sepsis, acute inflammation is attended by low blood pressure and blood clots, causing the organs to stop working. Only recently, the Brazilian football legend Socrates, died of the consequences of this condition. In a new study in the top journal Immunity, Peter Vandenabeele and colleagues of VIB-UGent described how blocking a particular form of cell death (necroptosis) fully protects mice against this fatal inflammation.

"This research opens up new perspectives for the treatment of fatal inflammatory diseases such as sepsis," says researcher Peter Vandenabeele of VIB and UGent. "By blocking necroptosis, we have found a possibly new target for a therapy."

Sepsis and SIRS

The Ghent scientists studied the Systemic Inflammatory Response Syndrome (SIRS). This is a severe inflammatory reaction affecting the entire body. It may be caused by an infection, such as sepsis, or by physical injury such as severe burns or a serious road accident.

Role of TNF in SIRS

The cytokine tumor necrosis factor (TNF) plays a crucial role in the occurrence of SIRS. The presence of TNF may trigger the cells to cause inflammation and programmed cell death. Inflammation is a necessary response in the body generated, among other things, to prevent or restore damage when injury and infections have been sustained. Programmed cell death can occur in two ways: via apoptosis or via necroptosis. The difference between the two forms of cell death lies among other things in communication with our immune system. Necroptosis usually provokes a strong reaction by the immune system whereas apoptosis proceeds unnoticed.

RIPK: potential therapeutic target for treatment of SIRS and sepsis

Peter Vandenabeele and his colleagues Linde Duprez, Nozomi Takahashi and Anje Cauwels have discovered that in mice eliminating apoptosis did not have any impact on lethal SIRS whereas eliminating nepcroptosis afforded full protection against the condition. The scientists managed to block nepcroptosis by eliminating RIPK (Receptor-interacting serine/threonine-protein kinase) molecules. The experiments showed that RIPK plays a crucial role in SIRS and sepsis. The molecule appears to constitute a potential therapeutic target for the treatment of SIRS and sepsis. Further research should clarify the potential applications of this discovery.


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Targeted antibacterial proteins may offer antibiotic alternative
2. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
3. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
4. Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
5. Lesser-known Escherichia coli types targeted in food safety research
6. Delivering drugs to the brain: New research into targeted treatment of Alzheimers
7. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
8. New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
9. UC to test targeted treatment for prostate cancer
10. Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles
11. New subtype of breast cancer responds to targeted drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the design of the ... to introduce it to top lab design architects from around the country at the ... of Industrial Design and Engineering Greg Casey will be at the show, where they ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging bio and technology start-ups, is hosting “Celebration Friday” (a ... double event will start with libations and networking at 3:30 p.m. at FITCI’s ...
(Date:4/20/2017)... Lilly and Company (NYSE: LLY ) will ... of migraine at the American Academy of Neurology (AAN) ... in Boston . ... and patient outcomes data for galcanezumab in patients with ... migraine headache days among patients with episodic migraine. Lilly ...
(Date:4/20/2017)... /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" ... Liver Congress ("ILC") 2017 of the European Association for the ... on the positive effects of PBI-4050 on reduction of ... metabolic syndrome. ... Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This ...
Breaking Biology Technology: